When should diabetic medications be stopped in patients who are terminal, severely frail, have advanced dementia, recurrent severe hypoglycemia, cannot maintain oral intake, are acutely ill, undergoing surgery or prolonged fasting, or have advanced renal failure (eGFR <15 mL/min/1.73 m²)?

When to Discontinue Diabetic Medications

Discontinue all anti-diabetic medications in terminal patients with type 2 diabetes who have ceased oral intake, shifting goals from long-term complication prevention to immediate symptom management and quality of life. 1

End-of-Life and Terminal Illness

• Complete medication discontinuation is reasonable for dying patients with type 2 diabetes, especially when oral intake has stopped, as the primary goals shift to symptom management rather than preventing long-term complications 1
• Type 1 diabetes patients may require a small amount of basal insulin even at end-of-life to prevent acute hyperglycemic complications and symptom burden, though no consensus exists 1
• Never discontinue insulin completely in type 1 diabetes patients, even terminally, as this causes acute hyperglycemic complications and increased symptom burden 1

Advanced Dementia and Severe Frailty

• Patients with advanced dementia or severe frailty should have less stringent glycemic targets (A1C ~8.0%) and medications causing hypoglycemia should be discontinued or dose-reduced 2
• Frail older adults are at higher risk for serious hypoglycemia than healthier, more-functional older adults, making aggressive glycemic control particularly dangerous 2
• Hypoglycemia in dementia patients can lead to brain cell degeneration and further cognitive decline, creating a vicious cycle 3

Recurrent Severe Hypoglycemia

When severe or frequent hypoglycemia occurs, discontinue sulfonylureas first due to their direct stimulation of insulin secretion regardless of blood glucose levels and minimal cardiovascular or renal benefits 1

Stepwise approach to hypoglycemia management:

• Step 1: Discontinue sulfonylureas (glipizide, glyburide, glimepiride) immediately, as they carry the highest hypoglycemia risk 2, 1
• Step 2: Reduce or discontinue insulin secretagogues (meglitinides like repaglinide, nateglinide) 2
• Step 3: Simplify complex insulin regimens by reducing basal and prandial doses 2, 1
• Step 4: Continue metformin if possible, as it has the lowest hypoglycemia risk among oral agents and provides cardiovascular benefits 1
• Avoid discontinuing all medications simultaneously, as this makes it difficult to identify the causative agent and can lead to rebound hyperglycemia 1

Inability to Maintain Oral Intake

• Discontinue all oral anti-diabetic medications when patients cannot maintain oral intake, as absorption becomes unreliable and hypoglycemia risk increases dramatically 1
• Metformin should be temporarily discontinued during dehydration, vomiting, or diarrhea due to increased lactic acidosis risk 2, 4
• Stable patients who can maintain oral intake should continue previous medications with focus on preventing both hypoglycemia and severe hyperglycemia through blood glucose monitoring 1

Acute Illness and Hospitalization

Implement "sick-day rules" where patients hold metformin and SGLT-2 inhibitors during any acute illness:

• Metformin must be discontinued during severe illness, hospitalization, or any condition compromising renal or hepatic function due to lactic acidosis risk 2, 1, 4
• SGLT-2 inhibitors should be discontinued in patients with severe symptoms to reduce risk of euglycemic or moderate hyperglycemic diabetic ketoacidosis 1
• Sulfonylureas should be reduced or temporarily discontinued when patients receive fluoroquinolones or sulfamethoxazole-trimethoprim, as these antimicrobials increase effective sulfonylurea dose and precipitate hypoglycemia 2

Surgery and Prolonged Fasting

• Metformin should be temporarily discontinued before procedures including imaging studies using iodinated contrast, during hospitalizations, and when acute illness may compromise renal or liver function 2
• Sulfonylureas and other insulin secretagogues should be held on the day of surgery due to unpredictable hypoglycemia risk during fasting 2

Advanced Renal Failure (eGFR <15 mL/min/1.73 m²)

Metformin is absolutely contraindicated when eGFR falls below 30 mL/min/1.73 m² due to inevitable accumulation and lactic acidosis risk 2, 4

Renal function-based medication decisions:

• eGFR <30 mL/min/1.73 m²: Discontinue metformin immediately 2, 1, 4
• eGFR 30-45 mL/min/1.73 m²: Reduce metformin dose and monitor renal function every 3-6 months 2
• eGFR <15 mL/min/1.73 m²: Prioritize hypoglycemia prevention above all else, as uremic hypoglycemia is common and has ominous prognostic implications 1, 5
• Patients with advanced renal failure should have glucose targets shifted to the upper end of the desired range, and all agents causing hypoglycemia should be dose-reduced or discontinued 1
• Hypoglycemia in renal failure is often a marker of multisystem failure with complex pathogenesis involving impaired renal insulin degradation, diminished renal gluconeogenesis, and poor nutrition 5

Organ Failure (Hepatic, Cardiac)

• Patients with organ failure should prioritize hypoglycemia prevention as the greatest priority, with glucose targets shifted to the upper end of the desired range 1
• Metformin is contraindicated in decompensated cirrhosis (Child-Pugh class B-C), especially with concomitant kidney dysfunction, due to impaired lactate clearance 4
• Metformin should be used with caution in congestive heart failure due to increased lactic acidosis risk 4

Overtreatment and Deintensification

An A1C value below 6.5% should prompt immediate reduction or discontinuation of medications that carry high hypoglycemia risk 1

Identifying overtreatment:

• Overtreatment of diabetes is common in older adults and should be avoided, with deintensification recommended when complex regimens can be simplified while maintaining individualized A1C targets 2, 1
• Simplification of insulin regimens reduces hypoglycemia and disease-related distress without worsening glycemic control 1
• For healthy older adults, target A1C <7.5%; for those with complex health status, target A1C <8.0% 1

Critical Pitfalls to Avoid

• Never discontinue metformin first when addressing hypoglycemia—it has the lowest hypoglycemia risk and provides cardiovascular benefits; discontinue sulfonylureas first 1
• Never continue metformin in advanced renal insufficiency (eGFR <30 mL/min/1.73 m²) despite its benefits, as lactic acidosis risk becomes unacceptable 2, 1, 4
• Never use glyburide in older adults—it is a longer-acting sulfonylurea with increased hypoglycemia risk and should be avoided entirely 2
• Never use chlorpropamide in older adults due to prolonged half-life and increased hypoglycemia risk that increases with age 2
• Avoid sliding-scale insulin regimens as they increase hypoglycemia risk 2